Else Nutrition Pushes Staged Collaboration With Danone
By Robb M. Stewart
Else Nutrition has plans for a staged collaboration with dairy giant Danone.
The company said Monday it signed a letter of intent that initially will cover a license agreement where Else's plant-based, soy-free products will be included in Danone's portfolio and be manufactured, marketed and commercialized by the European company. The company will negotiate opportunities beyond product commercialization.
The letter of intent was agreed after Danone completed a due diligence process, Else said. The companies expect to sign a definitive agreement by the end of March.
Earlier this month, Else launched its plant-based dairy-alternative drink for toddlers in the U.K., marking its first push into the multi-billion-dollar European market. Else in September began commercial production at a new U.S. facility in the Midwest that it expects will support its manufacturing demand for the coming years in North America, and last month it said its ready-to-drink kids' shakes would hit the shelves at more than 100 stores of a Canadian grocery chain in the province of Ontario.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
November 13, 2023 09:12 ET (14:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom